Skip to main content
Fig. 2 | BMC Rheumatology

Fig. 2

From: Incidence and predictors of fragility fracture in postmenopausal rheumatoid arthritis patients receiving oral bisphosphonates: a longitudinal observational study

Fig. 2

Receiver-operating curve analysis for evaluating the value of the baseline dose of methotrexate for predicting the development of future fragility fracture. The area under the curve was 0.61 (95% CI 0.47–0.75). A cutoff value of 4 mg/week was determined by the point closest to the upper left-hand corner of the graph with a sensitivity and specificity of 55.0% and 70.5%, respectively

Back to article page